The Goldman Sachs Group, Inc. 13D and 13G filings for Kiora Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-12 11:39 am Sale | 2024-12-31 | 13G | Kiora Pharmaceuticals, Inc. KPRX | GOLDMAN SACHS GROUP INC GS | 130 0.000% | -180,662 (-99.93%) | Filing |
| 2024-11-12 5:58 pm Purchase | 2024-09-30 | 13G | Kiora Pharmaceuticals, Inc. KPRX | GOLDMAN SACHS GROUP INC GS | 180,792 6.100% | 180,792 (New Position) | Filing |